Developing a holistic approach to cardio, metabolic and renal disease
By Hannah Balfour (European Pharmaceutical Review)
Pursuing new paths in targeted protein degradation drug development
By Ian Churcher (Amphista)
Rapid method development to overcome challenges of bi-specific antibody purification
By Alice Harrison (Lonza), Stuart Jamieson (Lonza)
2022 spells change for EU pharmaceutical legislation
By Hannah Balfour (European Pharmaceutical Review)
Developing broad-spectrum vaccines that target the heart of mutating viruses
By Alexandre Le Vert (Osivax)
Tackling fake pharmaceuticals: an industry united against counterfeit products
By Rich Quelch (Origin)
How can evidence-based medicine (EBM) methodology support drug withdrawals?
By Samantha Lane (Drug Safety Research Unit [DSRU])
Advancing cell therapies – γδ T cells and the combination…
By Hannah Balfour (European Pharmaceutical Review)